Substance P Receptor Antagonist 1 has potential therapeutic applications in central nervous system disorders (such as depression, anxiety, and schizophrenia), respiratory and inflammatory diseases (such as asthma and rheumatoid arthritis), gastrointestinal disorders (including ulcerative colitis and Crohn's disease), and pain transmission (including migraine).